| 1. |
- Aad, G., et al.
(författare)
-
- 2013
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- Aad, G., et al.
(författare)
-
- 2014
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Aad, G., et al.
(författare)
-
- 2013
-
Tidskriftsartikel (refereegranskat)
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Abazov, V. M., et al.
(författare)
-
Search for W' -> tb resonances with left- and right-handed couplings to fermions D0 Collaboration
- 2011
-
Ingår i: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 699:3, s. 145-150
-
Tidskriftsartikel (refereegranskat)abstract
- We present a search for the production of a heavy gauge boson, W', that decays to third-generation quarks, by DO Collaboration in p (p) over bar) collisions at root s = 1.96 TeV. We set 95% confidence level upper limits on the production cross section times branching fraction. For the first time, we set limits for arbitrary combinations of left-and right-handed couplings of the W' boson to fermions. For couplings with the same strength as for the standard model W boson, we set the following limits, assuming that there are right-handed neutrinos nu(R) for all three generations with M(W') > m(nu(R)): M(W') > 863 GeV for purely left-handed couplings, M(W') > 885 GeV for purely right-handed couplings, and M(W') > 916 GeV if both left-and right-handed couplings are present. The limit for right-handed couplings improves for M(W') < m(nu(R)) to M(W') > 890 GeV.
|
|
| 7. |
- Cung, T. -T., et al.
(författare)
-
Cyclosporine before PCI in Patients with Acute Myocardial Infarction
- 2015
-
Ingår i: New England Journal of Medicine. - 0028-4793. ; 373:11, s. 1021-1031
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODS In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTS A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval, 0.78 to 1.39; P = 0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONS In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.)
|
|
| 8. |
- Sodergren, Erica, et al.
(författare)
-
The genome of the sea urchin Strongylocentrotus purpuratus.
- 2006
-
Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 1095-9203 .- 0036-8075. ; 314:5801, s. 941-52
-
Tidskriftsartikel (refereegranskat)abstract
- We report the sequence and analysis of the 814-megabase genome of the sea urchin Strongylocentrotus purpuratus, a model for developmental and systems biology. The sequencing strategy combined whole-genome shotgun and bacterial artificial chromosome (BAC) sequences. This use of BAC clones, aided by a pooling strategy, overcame difficulties associated with high heterozygosity of the genome. The genome encodes about 23,300 genes, including many previously thought to be vertebrate innovations or known only outside the deuterostomes. This echinoderm genome provides an evolutionary outgroup for the chordates and yields insights into the evolution of deuterostomes.
|
|
| 9. |
- Jenkins, S. R., et al.
(författare)
-
Population dynamics of the intertidal barnacle Semibalanus balanoides at three European locations: spatial scales of variability
- 2001
-
Ingår i: Marine Ecology Progress Series. - : Inter-Research Science Center. - 0171-8630 .- 1616-1599. ; 217, s. 207-217
-
Tidskriftsartikel (refereegranskat)abstract
- Spatial variability in the population dynamics of the intertidal acorn barnacle Semibalanus balanoides was investigated using a hierarchical sampling programme. Variability in a number of population parameters (size distribution, density, % cover, absolute growth and instantaneous mortality) was determined separately for new recruits and adults over 3 spatial scales. Three locations, SW Ireland, the Isle of Man and the west coast of Sweden, which cover a large part of the European range of this species, were selected to investigate variability over a large spatial scale (100s of kilometres). Two smaller scales, shore (1000s of metres) and site (10s of metres) nested within each location were also used. In addition, temporal variation over two 6 mo periods was also examined in the Isle of Man and Ireland. Most variability for all population parameters occurred over the largest spatial scale (location). This was a direct result of differences between Sweden and the other 2 locations, the Isle of Man and Ireland, which showed highly similar levels of all population parameters. The population of S, balanoides at the Swedish location was characterised by high growth rates, large size, high levels of mortality and a large turnover of bare space. At the spatial scale 'shore', only 1 population parameter, the growth rate of recruits, showed variability. At the smallest scale of 'site', all parameters showed significant variability except growth rate of adults. Calculation of variance components showed that differences between replicates (spatial scale: <0.5 m) accounted for little of the overall variability, in general less than the scales of site and shore. Examination of temporal variability over two 6 mo periods revealed no difference between time periods and no significant interaction between temporal and spatial scales, Thus, there was consistency of spatial variability over time. The potential causes of variability in population parameters of S, balanoides at different spatial scales and the implications for future studies are discussed.
|
|
| 10. |
- Mewton, Nathan, et al.
(författare)
-
Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial)
- 2015
-
Ingår i: American Heart Journal. - : Elsevier BV. - 1097-6744 .- 0002-8703. ; 169:6, s. 6-766
-
Tidskriftsartikel (refereegranskat)abstract
- Background Both acute myocardial ischemia and reperfusion contribute to cardiomyocyte death in ST-elevation myocardial infarction (STEMI). The final infarct size is the principal determinant of subsequent clinical outcome in STEMI patients. In a proof-of-concept phase II trial, the administration of cyclosporine prior to primary percutaneous coronary intervention (PPCI) has been associated with a reduction of infarct size in STEMI patients. Methods CIRCUS is an international, prospective, multicenter, randomized, double-blinded, placebo-controlled trial. The study is designed to compare the efficacy and safety of cyclosporine versus placebo, in addition to revascularization by PPCI, in patients presenting with acute anterior myocardial infarction within 12 hours of symptoms onset and initial TIMI flow <= 1 in the culprit left anterior descending coronary artery. Patients are randomized in a 1: 1 fashion to 2.5 mg/kg intravenous infusion of cyclosporine or matching placebo performed in theminutes preceding PCI. The primary efficacy end point of CIRCUS is a composite of 1-year all-cause mortality, rehospitalization for heart failure or heart failure worsening during initial hospitalization, and left ventricular adverse remodeling as determined by sequential transthoracic echochardiography. Secondary outcomes will be tested using a hierarchical sequence of left ventricular (LV) ejection fraction and absolute measurements of LV volumes. The composite of death and rehospitalization for heart failure or heart failure worsening during initial hospitalization will be further assessed at three years after the initial infarction. Results Recruitment lasted from April 2011 to February 2014. The CIRCUS trial has recruited 975 patients with acute anterior myocardial infarction. The 12-months results are expected to be available in 2015. Conclusions The CIRCUS trial is testing the hypothesis that cyclosporine in addition to early revascularization with PPCI compared to placebo in patients with acute anterior myocardial infarction reduces the incidence of death, heart failure and adverse LV remodeling at one-year follow-up.
|
|
